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 Previous work indicates that intranasal inhalation of oxytocin improves face recognition 
skills, raising the possibility that it may be used in security settings.  However, it is unclear 
whether oxytocin directly acts upon the core face-processing system itself, or indirectly 
improves face recognition via affective or social salience mechanisms.  In a double-blind 
procedure, 60 participants received either an oxytocin or placebo nasal spray before 
completing the One-in-Ten task – a standardized test of unfamiliar face recognition 
containing target-present and target-absent line-ups.  Participants in the oxytocin condition 
outperformed those in the placebo condition on target-present trials, yet were more likely to 
make false-positive errors on target-absent trials.  Signal detection analyses indicated that 
oxytocin induced a more liberal response bias, rather than increasing accuracy per se.  These 
findings support a social salience account of the effects of oxytocin on face recognition, and 
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Oxytocin Increases Bias, but not Accuracy, in Face Recognition Line-Ups 
 
Oxytocin is a nonapeptide that plays a fundamental role in social cognition (Heinrichs et al., 
2009).  Recent evidence demonstrates that intranasal inhalation of oxytocin improves facial 
identity recognition in both typical participants (Guastella et al., 2008; Rimmele et al., 2009; 
Savaskan et al., 2008) and those with prosopagnosia (Bate et al., 2014), although the precise 
underpinnings of this effect remain unclear.  Understanding the effects of oxytocin on face 
recognition is an important issue, given the hormone may be useful for specific face 
recognition tasks within security or forensic settings. 
It is possible that oxytocin acts upon the core face-processing system (Haxby et al., 
2000), and some neuroimaging evidence supports this possibility (e.g. Domes et al., 2010; 
Labuschagne et al., 2010).  Alternatively, oxytocin may affect face-processing more 
indirectly by modulating affective or social salience mechanisms. The hypothesis that 
oxytocin increases social salience, either via an affective (Shamay-Tsoory et al., 2009; 
Theodoridou et al., 2013) or approach-withdrawal (Ditzen et al., 2009; Kemp & Guastella, 
2011) mechanism, is supported by several lines of evidence.  Firstly, neuroimaging studies 
suggest that oxytocin influences affective areas of the brain (e.g. Gamer et al., 2010; Petrovic 
et al., 2008). Secondly, in other areas of oxytocin research, such as economic games and 
social judgements, social salience hypotheses have been used to account for pro- (and 
sometimes anti-) social effects of the hormone (e.g. Shamay-Tsoory et al., 2009; De Dreu et 
al., 2010, 2011, DeClerk et al., 2010; Bartz et al., 2011). Finally, several studies examining 
the influence of oxytocin on facial identity recognition have found mixed results depending 
on the emotional expression displayed upon the face (Guastella et al., 2008; Saskavan et al., 
2008).  These investigations raise the possibility that oxytocin may only improve face 
recognition in certain social or affective conditions. 





A novel means of exploring this issue is to investigate the influence of oxytocin on 
face recognition within line-up scenarios, where multiple faces are simultaneously displayed 
for recognition and a target face may or may not be present. Indeed, if oxytocin acts upon the 
face recognition system itself, performance should improve in both target-present and target-
absent conditions.  Alternatively, given the pro-social effects of oxytocin described above, 
the hormone may influence affective or social salience mechanisms, perhaps by making a 
perceiver’s response bias more liberal.  If this is the case, performance would be impeded in 
target-absent trials, due to a greater number of false-positive errors.  Such findings would 
have important implications for real-world use of oxytocin, particularly if it encourages the 
misidentification of innocent individuals.  The current study aimed to examine this 
hypothesis, by investigating the influence of oxytocin on performance on the One-in-Ten test 
(Bruce et al., 1999) – a standardized test of unfamiliar face recognition consisting of target-






60 participants (34 female; Mean age = 22.8 years, SD = 3.3) were randomly assigned in a 
double-blind between-subjects procedure to receive either oxytocin or placebo spray (gender 
was evenly dispersed between conditions).  The exact protocols, including exclusion criteria 
and administration procedures, are described fully in Bate et al. (2014).  Ethical approval was 
granted by Bournemouth University’s Ethics Board, and participants received a small 
monetary payment in exchange for their time. 
 





Stimuli and Materials 
The One-In-Ten test: The face recognition task used in this study was the One-In-Ten test 
(Bruce et al., 1999): a test containing 20 target-present and 20 target-absent trials, that has 
been well-used and validated within the psychological literature (e.g. Bindemann et al., 2012; 
Megreya & Burton, 2007).  In each of the 40 randomly-presented trials, participants study a 
single target face until they are confident they can identity it from a subsequent line-up.  
Target faces are extracted from high-quality video footage, and measure 155 pixels in width 
and 200 pixels in height at a screen resolution of 72(?) ppi.  After the participant presses a 
key to indicate that encoding is complete, the target is instantly replaced by a line-up of ten 
faces, each measuring 132 pixels in width and 200 pixels in height.  All faces display a 
neutral expression and are not cropped to exclude the external features, in order to maintain 
the ecological validity of the task.   
Participants are required to use defined keys on the keyboard to indicate which face (if any) 
matches the target face.  To encourage maximum performance, no time limits are imposed on 
the participant in any part of this task (see Bruce et al., 1999).  For target-present trials, 
participants can make a correct identification (a ‘hit’), or one of two incorrect responses: 
either a ‘misidentification’ (i.e. the incorrect identification of a distractor face) or a ‘miss’ 
(the incorrect response that a target is absent).  In target-absent trials, the correct response is 
referred to as a ‘correct rejection’, and incorrect responses as ‘false-positives’. 
 
The Multidimensional Mood Questionnaire (MMQ): General affect was measured throughout 
the experiment using the MMQ (Steyer, Schwenkmezger, Notz, & Eid, 1997).  This self-
report questionnaire is composed of three sub-scales (good-bad, awake-tired and calm-
nervous), and was used to assess the possible mood-altering effects of oxytocin, and to 
control for non-specific effects of attention and wakefulness. 







Participants initially received a single intranasal dose of 24 IU of either oxytocin (Syntocinon 
Spray, Novartis) or placebo (identical to the experimental spray with the exception of the 
oxytocin) spray.  Following inhalation, participants sat quietly for 45 minutes to allow central 
oxytocin levels to plateau (Born et al., 2002), and then completed the One-In-Ten task.  Each 
participant was required to complete the MMQ at three intervals across the experiment: 
immediately following inhalation, after the 45 min resting period, and after the One-In-Ten 





First, the time taken to encode target faces was examined, and no differences were observed 
between the oxytocin and placebo condition (all ps > .05).  Second, we examined only the 
correct responses from the test phase (i.e. the hits and correct rejections).  Specifically, a 2 
(spray: oxytocin, placebo) x 2 (line-up: target-present, target-absent) mixed design analysis of 
variance (ANOVA) revealed a main effect of line-up, with a greater number of correct 
responses for target-present (M = 13.40, SE = .40) than target-absent (M = 11.60, SE = .48) 
trials, F(1,58) = 9.373, p = .003, ƞp2 = .139, 95% CI [.03-.27].  Although overall performance 
did not differ between the oxytocin (M = 12.47, SE = .46) and placebo (M = 12.53, SE = .46) 
sprays, F(1,58) = .011, p = .919, ƞp2 = .001, 95% CI [.00-.05], the two factors did interact 
F(1,58) = 8.036, p = .006, ƞp2 = .122, 95% CI [.02-.25] (see Figure 1). 
 





Figure 1: Number of correct responses for target-present and target-absent line-ups, under 
oxytocin and placebo conditions. 
 
 
Planned follow-up analyses indicated that this interaction was facilitated by better 
performance in the oxytocin condition for target-present compared to target-absent trials, but 
there was no such difference in the placebo condition, F(1,29) = 26.573, p = .001, ƞp2 = .478, 
95% CI [.24-.62] and F(1,29) = .019, p = .891, ƞp2 = .001, 95% CI [.00-.03], respectively.  
Further analyses indicated that performance in the target-present condition was indeed better 
in the oxytocin compared to the placebo condition, yet revealed a trend towards the converse 
pattern in the target-absent condition, F(1,58) = 4.064, p = .048, ƞp2 = .065, 95% CI [.00-.18] 
and F(1,58) = 3.311, p = .074, ƞp2 = .054, 95% CI [.00-.17], respectively.   
Third, we analysed sensitivity (d’ identification) and bias (criterion c), to examine 
whether oxytocin improved overall performance or changed participants’ response bias. 
Sensitivity was calculated by combining hits with false-positive scores; bias was calculated 
by combining all positive responses across both trial types (hits, misidentifications, and false-
positives: MacMillan and Creelman, 2005). A univariate ANOVA on each measure revealed 









































placebo d’: M = 0.69, SE = 0.15), F(1,58) = .005, p = .946, ƞp2 = .000, 95% CI [.00-.00], but 
participants in the oxytocin condition (c = -0.61, SE = .08) showed a more liberal response 
bias (i.e., more positive responses) than participants in the placebo condition (c = -0.22, SE = 
.08), F(1,58) = 11.83, p = .001, ƞp2 = .169, 95% CI [.05-.31].  
Fourth, we examined the type of errors that were made within the target-present 
condition.  Specifically, the proportion of misidentifications and misses were calculated for 
each participant, and an univariate ANOVA indicated that oxytocin participants made more 
misidentification errors, whereas placebo participants made more misses, F(1,58) = 10.067, p 
= .002, ƞp2 = .148, 95% CI [.03-.28] (see Figure 2). 
 
Figure 2: Proportion of misidentification errors in target-present line-ups, under oxytocin and 
placebo conditions.  The remaining errors are misses. 
 
 
Finally, a mixed factorial MANOVA examined the MMQ scores and revealed a main effect 
of time, F(6,53) = 5.103, p = .001, ƞp2 = .366, 95% CI [.13-.45].  Specifically, regardless of 
spray, participants felt less ‘good’, ‘awake’, and ‘nervous’ at the end of the testing session: 











































.135, 95% CI [.05-.22] and F(2,116) = 4.939, p = .015, ƞp2 = .078, 95% CI [.01-.16], 
respectively.  No main effect of spray or interaction between time and spray was observed, 
F(3,56) = .393, p = .759, ƞp2 = .021, 95% CI [0-.06] and F(6,53) = .884, p = .513, ƞp2 = .091, 
95% CI [0-.13], respectively, indicating that the findings cannot be attributed to potential 





This study investigated the effect of intranasal inhalation of oxytocin on face recognition 
performance in target-present and target-absent line-ups. Oxytocin did not improve overall 
accuracy, but participants who inhaled oxytocin were more accurate in target-present trials 
and somewhat less accurate in target-absent trials compared to those who inhaled a placebo 
spray. When participants did make errors in the target-present trials, those in the oxytocin 
condition were more likely to make misidentification errors (responding “present” but 
selecting the wrong face) than misses (responding “absent”). In other words, participants in 
the oxytocin condition showed a general increase in bias to respond “present”. This pattern of 
results could not be accounted for by a speed-accuracy trade-off or changes in mood or 
arousal.  
Our pattern of results argues against the hypothesis that oxytocin acts directly on the 
face-processing system. At first glance, these results sit at odds with other studies that have 
found an increase in face recognition performance after inhalation of oxytocin (e.g., 
Hertzmann et al., 2013; Rimmele et al., 2009; Guastella et al., 2008; Saskavan et al., 2008). 
Indeed these are the first results to link oxytocin with a more liberal response bias – Blandon-
Gitlin et al. (2013, Experiment 2) and Saskavan et al. (2008) found a more conservative 





pattern of responding under oxytocin conditions. However, it is possible that the 
methodological differences between this and previous studies can account for the differing 
patterns of results. For example, previous studies have generally examined the influence of 
oxytocin on face memory (specifically, face encoding), as opposed to face matching – that is, 
oxytocin was administered prior to or just after encoding, and recognition tested in a separate 
block between 30 mins and 24 hours later (e.g., Herzmann et al., 2012; Guastella et al., 2008; 
Rimmele et al., 2009; Saskavan et al., 2008). The factors that could make oxytocin beneficial 
for face encoding (i.e., increased attention to socially salient elements of the face and/or 
increased emotional salience) could also be detrimental in matching tasks: if oxytocin 
increased the salience of all the line-up faces, participants could have mistaken this salience 
for familiarity, leading to the false positive errors observed in the current study.  
Alternatively, the format of the test may explain the differences between the current 
results and previous studies. Research into oxytocin and face recognition has almost 
exclusively used old/new tests, and the introduction of a line-up may have allowed 
participants to use alternative decision strategies. Specifically, participants in the oxytocin 
condition may resort to a “next best” choice when the target is not present, whereas 
participants in the placebo condition may have judged each face on a match/no match criteria 
(analogous to proposed strategies used in simultaneous and sequential eyewitness line-ups, 
see Leach, Cutler, & Van Wallendael, 2009, for a review). Currently, though, it is unclear 
what mechanisms could support this strategy shift, and how they relate to the neural networks 
affected by oxytocin.  
In sum, this study adds to the growing body of evidence that intranasal inhalation of 
oxytocin is not universally beneficial for social cognition (Bartz et al., 2011; Hertzmann et 
al., 2012). While oxytocin may improve face recognition under some circumstances, such as 
an old/new recognition task, there is no discernable benefit of oxytocin in a face-matching 





task using line-up arrays. Currently, it is unclear which of these factors (matching vs 
encoding; old/new vs line-up; or a combination of both) resulted in the increased bias 
observed in the current study. Further research with simple face matching tasks, face memory 
tasks using line-ups, and oxytocin inhalation before recognition (as opposed to encoding), 
should clarify when and why oxytocin modulates face recognition. This in turn will provide 
guidance as to whether oxytocin is a viable tool in applied face recognition scenarios, such as 
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